NO20044132L - Legemidler som inneholder aktive ingredienser som senker kolesterolnivaet med tidsforsinket frigjoring av det aktive middelet - Google Patents

Legemidler som inneholder aktive ingredienser som senker kolesterolnivaet med tidsforsinket frigjoring av det aktive middelet

Info

Publication number
NO20044132L
NO20044132L NO20044132A NO20044132A NO20044132L NO 20044132 L NO20044132 L NO 20044132L NO 20044132 A NO20044132 A NO 20044132A NO 20044132 A NO20044132 A NO 20044132A NO 20044132 L NO20044132 L NO 20044132L
Authority
NO
Norway
Prior art keywords
delayed release
cholesterol levels
drugs containing
lower cholesterol
active agent
Prior art date
Application number
NO20044132A
Other languages
English (en)
Inventor
Peter Kraass
Original Assignee
Ratiopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm Gmbh filed Critical Ratiopharm Gmbh
Publication of NO20044132L publication Critical patent/NO20044132L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20044132A 2002-03-07 2004-09-29 Legemidler som inneholder aktive ingredienser som senker kolesterolnivaet med tidsforsinket frigjoring av det aktive middelet NO20044132L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10209979A DE10209979A1 (de) 2002-03-07 2002-03-07 Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung
PCT/EP2003/002328 WO2003074034A1 (de) 2002-03-07 2003-03-06 Arzneimittel mit cholesterolspiegel-senkenden wirkstoffen mit zeitverzögerter wirkstofffreisetzung

Publications (1)

Publication Number Publication Date
NO20044132L true NO20044132L (no) 2004-09-29

Family

ID=27771068

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044132A NO20044132L (no) 2002-03-07 2004-09-29 Legemidler som inneholder aktive ingredienser som senker kolesterolnivaet med tidsforsinket frigjoring av det aktive middelet

Country Status (11)

Country Link
US (1) US20050203186A1 (no)
EP (1) EP1480623A1 (no)
JP (1) JP2005526739A (no)
AU (1) AU2003218701A1 (no)
BR (1) BR0308229A (no)
CA (1) CA2478425A1 (no)
DE (1) DE10209979A1 (no)
NO (1) NO20044132L (no)
PL (1) PL372720A1 (no)
RU (1) RU2004127193A (no)
WO (1) WO2003074034A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1563837A1 (en) * 2004-02-03 2005-08-17 Ferrer Internacional, S.A. Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
WO2005115380A2 (en) * 2004-05-27 2005-12-08 Dexcel Pharma Technologies Ltd Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
DK1781265T3 (da) * 2004-08-25 2010-08-02 Essentialis Inc Farmaceutiske formuleringer af kalium ATP-kanal-åbnere og anvendelser deraf
CA2588215A1 (en) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
JP5543110B2 (ja) 2006-01-05 2014-07-09 エッセンシャリス，インク． カリウムａｔｐチャネルオープナの塩およびその使用
US7427414B2 (en) * 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
EP1825848A3 (de) * 2006-02-10 2010-03-03 Stada Arzneimittel Ag Stabile pharmazeutische Zusammensetzungen umfassend einen HMG-CoA-Reduktase Inhibitor
EP1818050A1 (de) * 2006-02-10 2007-08-15 Stada Arzneimittel Ag Stabile pharmazeutische Zusammensetzungen umfassend einen HMG-CoA-Reduktase Inhibitor
DE102006006532B4 (de) * 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
FR2904225B1 (fr) * 2006-07-28 2010-08-13 Bouchara Recordati Compositions pharmaceutiques de substances actives difficilement detournables de la voie d'administration a laquelle elles sont destinees
CA2692160A1 (en) * 2007-07-02 2009-01-08 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
AU2009208610A1 (en) * 2008-01-30 2009-08-06 Lupin Limited Modified release formulations of HMG CoA reductase inhibitors
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
AR089765A1 (es) 2012-01-23 2014-09-17 Bayer Oy Un sistema para el suministro de un farmaco

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780319A (en) * 1985-07-08 1988-10-25 Merck & Co., Inc. Organic acids as catalysts for the erosion of polymers
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
DE9015551U1 (no) * 1990-11-14 1992-03-12 Roehm Gmbh, 6100 Darmstadt, De
US5422121A (en) * 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
DE10012555A1 (de) * 2000-03-15 2001-09-20 Merck Patent Gmbh Glucocorticoide in einer Modified Release-Formulierung
US6761895B2 (en) * 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof

Also Published As

Publication number Publication date
WO2003074034A1 (de) 2003-09-12
RU2004127193A (ru) 2005-09-10
EP1480623A1 (de) 2004-12-01
PL372720A1 (en) 2005-07-25
CA2478425A1 (en) 2003-09-12
AU2003218701A1 (en) 2003-09-16
JP2005526739A (ja) 2005-09-08
DE10209979A1 (de) 2003-09-25
US20050203186A1 (en) 2005-09-15
BR0308229A (pt) 2004-12-28

Similar Documents

Publication Publication Date Title
IL245365A0 (en) ATP-linked cassette transport modulators, pharmaceutical preparations containing them and their uses
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
NO20044132L (no) Legemidler som inneholder aktive ingredienser som senker kolesterolnivaet med tidsforsinket frigjoring av det aktive middelet
DK1792927T3 (da) Ny blokcopolymer, micelletilberedning og anticancermiddel indeholdende samme som aktiv ingrediens
PT1439829E (pt) Medicamento contendo 3-(3-dimetilamino-1-etil-2-metilpropil)-fenol proporcionando libertacao retardada da substancia activa
DK1498411T3 (da) Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
DE60331153D1 (de) Reboxetin enthaltende tablette mit verzögerter wirkstoffabgabe
ZA200705750B (en) Compositions and methods for stabilizing active pharmaceutical ingredients
IL178128A0 (en) Salts of 3-0-(3',3'-dimethyl-succinyl) betulinic acid and pharmaceutical compositions containing the same
IL178297A0 (en) Hydrazide derivatives and pharmaceutical compositions containing the same
NO20032181D0 (no) Anvendelse av CCI-779 som et antineoplastisk middel
NO20044054L (no) Administrering av midler for behandling av betennelse
DE602005016551D1 (de) Stabilisierte supergesättigte feste lösungen von steroidalen arzneimitteln
HK1070053A1 (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
NO20026037L (no) Sötvareprodukt som inneholder aktive bestanddeler
IL176538A0 (en) Steroid derivatives and pharmaceutical compositions containing the same
DK1557415T3 (da) Heterocykliske forbindelser og antitumorlægemidler indeholdende samme som den aktive ingrediens
NO20052952D0 (no) Farmasoytisk sammensetning som innbefatter mikropartikler
IL183689A (en) Pharmaceutical compositions for improving the structure and function of arterioles
EP1919288A4 (en) FAMOTIDINE- AND IBUPROGEN-BASED MEDICAMENTS AND THEIR ADMINISTRATION
HK1105202A1 (en) Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient
DK1053746T3 (da) Anvendelse af bionedbrydelige mikrokugler, som frigiver et anticancermiddel, til behandling af glioblastomer
IL177496A0 (en) Amido-substituted hydroxy -6-phenylphenanthridine derivatives and pharmaceutical compositions containing the same
EP1419785A4 (en) MEDICAMENTS CONTAINING A CHYMASE INHIBITOR AND ACE INHIBITOR AS ACTIVE INGREDIENTS
IL181445A0 (en) Use of (halobenzyloxy)benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium selective modulators

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application